Income Statement DiaSorin S.p.A.
Equities
DIA
IT0003492391
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 70.46 EUR | +1.44% |
|
+11.49% | +2.68% |
| 05-15 | DiaSorin repurchases shares worth over EUR1 million | AN |
| 05-15 | Indices in the red; Brent rises toward USD109 | AN |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 1.24B | 1.36B | 1.15B | 1.19B | 1.2B | |||||
Total Revenues | 1.24B | 1.36B | 1.15B | 1.19B | 1.2B | |||||
Cost of Goods Sold, Total | 413M | 461M | 407M | 403M | 418M | |||||
Gross Profit | 825M | 901M | 741M | 782M | 778M | |||||
Selling General & Admin Expenses, Total | 305M | 415M | 414M | 415M | 408M | |||||
R&D Expenses | 70.09M | 96.9M | 90.95M | 91.57M | 95.01M | |||||
Other Operating Expenses | 8.67M | 13.64M | 6.32M | 9.32M | -348K | |||||
Other Operating Expenses, Total | 384M | 526M | 512M | 515M | 503M | |||||
Operating Income | 441M | 375M | 230M | 267M | 275M | |||||
Interest Expense, Total | -19.42M | -34.07M | -28.29M | -26.39M | -23.42M | |||||
Interest And Investment Income | 284K | 9.64M | 15.37M | 12.92M | 8.48M | |||||
Net Interest Expenses | -19.13M | -24.43M | -12.92M | -13.47M | -14.94M | |||||
Income (Loss) On Equity Invest. | - | - | - | - | - | |||||
Currency Exchange Gains (Loss) | 2M | - | - | - | - | |||||
Other Non Operating Income (Expenses) | -476K | -354K | -2.12M | -3.57M | -3.08M | |||||
EBT, Excl. Unusual Items | 423M | 350M | 214M | 250M | 257M | |||||
Restructuring Charges | - | - | - | - | - | |||||
Merger & Related Restructuring Charges | -1.92M | - | - | -6.91M | -38.89M | |||||
Gain (Loss) On Sale Of Investments | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Assets | - | - | - | - | - | |||||
Asset Writedown | - | - | - | - | - | |||||
Other Unusual Items | -21.9M | -24.06M | -13.25M | -329K | -6.15M | |||||
EBT, Incl. Unusual Items | 399M | 326M | 201M | 242M | 212M | |||||
Income Tax Expense | 88.6M | 85.83M | 42.71M | 55.39M | 61.57M | |||||
Earnings From Continuing Operations | 311M | 240M | 159M | 187M | 150M | |||||
Net Income to Company | 311M | 240M | 159M | 187M | 150M | |||||
Minority Interest | 236K | 797K | 1.34M | 1.05M | 5.59M | |||||
Net Income - (IS) | 311M | 241M | 160M | 188M | 156M | |||||
Net Income to Common Incl Extra Items | 311M | 241M | 160M | 188M | 156M | |||||
Net Income to Common Excl. Extra Items | 311M | 241M | 160M | 188M | 156M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 5.44 | 4.17 | 2.87 | 3.37 | 2.92 | |||||
Basic EPS - Continuing Operations | 5.44 | 4.17 | 2.87 | 3.37 | 2.92 | |||||
Basic Weighted Average Shares Outstanding | 57.12M | 57.75M | 55.75M | 55.87M | 53.3M | |||||
Net EPS - Diluted | 5.4 | 4.15 | 2.87 | 3.37 | 2.85 | |||||
Diluted EPS - Continuing Operations | 5.4 | 4.15 | 2.87 | 3.37 | 2.85 | |||||
Diluted Weighted Average Shares Outstanding | 57.59M | 58.05M | 55.75M | 55.87M | 54.6M | |||||
Normalized Basic EPS | 4.63 | 3.8 | 2.43 | 2.81 | 3.11 | |||||
Normalized Diluted EPS | 4.6 | 3.78 | 2.43 | 2.81 | 3.04 | |||||
Dividend Per Share | 1.05 | 1.1 | 1.15 | 1.2 | 1.3 | |||||
Payout Ratio | 17.59 | 23.68 | 36.89 | 32.58 | 40.83 | |||||
American Depositary Receipts Ratio (ADR) | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |||||
Supplemental Items | ||||||||||
EBITDA | 515M | 482M | 333M | 365M | 370M | |||||
EBITA | 477M | 434M | 283M | 323M | 329M | |||||
EBIT | 441M | 375M | 230M | 267M | 275M | |||||
Effective Tax Rate - (Ratio) | 22.19 | 26.33 | 21.22 | 22.85 | 29.1 | |||||
Total Current Taxes | 92.75M | 65.89M | 57.89M | 64.69M | 51.7M | |||||
Total Deferred Taxes | -1.6M | 22.99M | -12.99M | -7.94M | 7.53M | |||||
Normalized Net Income | 265M | 220M | 135M | 157M | 166M | |||||
Interest on Long-Term Debt | 8.26M | 12.26M | 12.36M | 13.48M | 13.68M | |||||
Non-Cash Pension Expense | 747K | 206K | - | 1.16M | - | |||||
Supplemental Operating Expense Items | ||||||||||
Selling and Marketing Expenses | 211M | 292M | 286M | 288M | 284M | |||||
General and Administrative Expenses | 93.27M | 123M | 129M | 128M | 125M | |||||
Research And Development Expense From Footnotes | 70.09M | 96.9M | 90.95M | 91.57M | 95.01M | |||||
Stock-Based Comp., G&A Exp. (Total) | 6.43M | 9.54M | 10.04M | 11.11M | 11.11M | |||||
Stock-Based Comp., Other (Total) | - | - | - | - | - | |||||
Total Stock-Based Compensation | 6.43M | 9.54M | 10.04M | 11.11M | 11.11M |
- Stock Market
- Equities
- DIA Stock
- Financials DiaSorin S.p.A.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















